Skip to content
Screener

Erasca, Inc. ERAS Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Pfizer logo
PfizerPFE
$207.62B-0.2%
Amgen logo
AmgenAMGN
$95.64B+8.8%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$4.32B+77.9%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$435.79M+58.9%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$6.34B+1,466%
Enterprise value$6.34B+1,533%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Erasca, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216788
Line itemMarch 31, 2026December 31, 2025
Stockholders' equity:
Preferred stock, $0.0001 par value; 80,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 800,000,000 shares authorized at March 31, 2026 and December 31, 2025; 310,806,888 and 284,159,076 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively3128
Additional paid-in capital1,469,8451,216,724
Accumulated other comprehensive (loss) income(699)628
Accumulated deficit(1,075,649)(892,209)
Total stockholders' equity393,528325,171
Total liabilities and stockholders' equity$461,234$396,154

Item 1. Financial Statements.

FAQ

What is Erasca, Inc.'s total liabilities & equity?
Erasca, Inc. (ERAS) reported total liabilities & equity of $461.23M in Q1 2026.
How has Erasca, Inc.'s total liabilities & equity changed year-over-year?
Erasca, Inc.'s total liabilities & equity decreased by 2.1% year-over-year, from $471.24M to $461.23M.
What is the long-term trend for Erasca, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Erasca, Inc.'s total liabilities & equity has grown at a 26.0% compound annual growth rate (CAGR), from $124.83M to $396.15M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Erasca, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude